Mesenchymal stem cell therapy for neonatal intraventricular hemorrhage: a long way to go?

The goal of neonatal medicine is intact survival, or to prevent the complications and improve the neurodevelopmental outcome of these vulnerable population. Intraventricular hemorrhage (IVH) is one of the most common and devastating morbidities among the preterm infants, especially those born as very low birth weight infants (VLBWI) (1). The severity of IVH is known to be inversely correlated with neurodevelopmental outcomes, and most of the infants affected by severe (grade 3 or 4) IVH die or develop neurodevelopmental sequelae. Currently, there is no effective therapeutic approach for severe IVH.